Effects of Dapagliflozin, a Sodium-Glucose Cotransporter-2 Inhibitor, on Hemoglobin A1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy Full Text
Diabetes Care,  Clinical Article

Rosenstock J et al. – In patients with type 2 diabetes inadequately controlled on pioglitazone, the addition of dapagliflozin further reduced HbA1c levels and mitigated the pioglitazone–related weight gain without increasing hypoglycemia risk.

Methods
  • Treatment-naive patients or those receiving metformin, sulfonylurea, or thiazolidinedione entered a 10-week pioglitazone dose-optimization period with only pioglitazone.
  • They were then randomized, along with patients previously receiving pioglitazone ≥30 mg, to 48 weeks of double-blind dapagliflozin 5 (n = 141) or 10 mg (n = 140) or placebo (n = 139) every day plus open-label pioglitazone.
  • The primary objective compared hemoglobin A1c (HbA1c) change from baseline with dapagliflozin plus pioglitazone versus placebo plus pioglitazone at week 24.
  • Primary analysis was based on ANCOVA model using last observation carried forward; all remaining analyses used repeated-measures analysis.

Results
  • At week 24, the mean reduction from baseline in HbA1c was -0.42% for placebo versus -0.82 and -0.97% for dapagliflozin 5 and 10 mg groups, respectively (P = 0.0007 and P < 0.0001 versus placebo).
  • Patients receiving pioglitazone alone had greater weight gain (3 kg) than those receiving dapagliflozin plus pioglitazone (0.7–1.4 kg) at week 48.
  • Through 48 weeks: hypoglycemia was rare; more events suggestive of genital infection were reported with dapagliflozin (8.6–9.2%) than placebo (2.9%); events suggestive of urinary tract infection showed no clear drug effect (5.0–8.5% for dapagliflozin and 7.9% for placebo); dapagliflozin plus pioglitazone groups had less edema (2.1–4.3%) compared with placebo plus pioglitazone (6.5%); and congestive heart failure and fractures were rare.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Endocrinology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Endocrinology Articles

1 Effects of 12 weeks high-dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency – A double-blind, randomized, placebo-controlled trial Metabolism, July 9, 2014    Clinical Article

2 Hemoglobin A1c less than 6.5% on admission increases risk for in-hospital and 1-year mortality in patients with diabetes and chest pain Cardiovascular Endocrinology, September 2, 2014    Clinical Article

3 New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care, September 12, 2014    Clinical Article

4 New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using basal and mealtime insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1) Diabetes Care, August 1, 2014    Clinical Article

5 Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study Obesity Research & Clinical Practice, July 24, 2014    Clinical Article

6 Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: Meta-analysis of five randomized controlled trials Advances in Therapy, September 10, 2014    Evidence Based Medicine

7 Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation Acta Diabetologica, September 15, 2014    Clinical Article

8 The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in Type 1 Diabetes Journal of Diabetes and its Complications, August 22, 2014    Clinical Article

9 Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study Diabetes Care, September 11, 2014    Clinical Article

10 New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care, September 22, 2014    Clinical Article

11 The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR) Diabetes Research and Clinical Practice, September 9, 2014    Clinical Article

12 Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study) Journal of Internal Medicine, August 1, 2014    Clinical Article

13 Regular breakfast consumption and type 2 diabetes risk markers in 9- to 10-year-old children in the child heart and health study in england (CHASE): A cross-sectional analysis Full Text PLoS Medicine, September 8, 2014    Free full text    Clinical Article

14 New insulin glargine 300 units·ml-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units·ml-1 Diabetes Care, September 15, 2014    Clinical Article

15 Efficacy and safety of vitamin D3 in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials Full Text Chinese Medical Journal, August 26, 2014    Free full text    Review Article

16 Lifestyle and clinical factors associated with elevated C-reactive protein among newly diagnosed Type 2 diabetes mellitus patients: a cross-sectional study from the nationwide DD2 cohort Full Text BMC Endocrine Disorders, August 29, 2014    Free full text    Clinical Article

17 An early pregnancy HbA1c ≥5.9% (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes Diabetes Care, September 12, 2014    Clinical Article

18 Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator–controlled, adaptive proof-of-concept phase 2 study Diabetes Care, September 19, 2014    Clinical Article

19 Drugs that interact with levothyroxine; an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS) Clinical Endocrinology, July 18, 2014    Clinical Article

20 Adiponectin is better predictor of subclinical atherosclerosis than liver function tests in patients with nonalcoholic fatty liver disease Journal of the American Society of Hypertension, July 18, 2014    Clinical Article

Indexed Journals in Endocrinology: Endocrinology, Journal of Endocrinology, Clinical Endocrinology, Diabetesmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close